Lopinavir
Based on 20 publication(s) in Google Scholar
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 192725-17-0
- Formula: C37H48N4O5
- Molecular Weight:628.80
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Lopinavir
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2021 May 29;6(1):212. [Abstract]
- Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
- Nat Commun. 2020 Sep 4;11(1):4417. [Abstract]
- Bone Res. 2025 Jun 3;13(1):58. [Abstract]
- Adv Sci (Weinh). 2024 Jun 18:e2307751. [Abstract]
- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Fundam Res. 2023 Apr 7;5(6):2975-2982. [Abstract]
- J Photochem Photobiol A Chem. 2025 Nov 15;473:116930.
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819. [Abstract]
- Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00872-20. [Abstract]
- Antiviral Res. 2022 Dec:208:105463. [Abstract]
- Antiviral Res. 2020 Jun;178:104786. [Abstract]
- Viruses. 2020 Jun 10;12(6):628. [Abstract]
- J Chem. 2025 Oct 15.
- Biochem Biophys Res Commun. 2019 Sep 10;517(1):125-131. [Abstract]
- Microbe. 2025 Oct 14.
- bioRxiv. 2024 Feb 3.
- Universidade de São Paulo. 2020 Sep.
- University of Oxford. 2019 Jul.
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
IF
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
|
HIV-1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | IC50 |
1.7 μM
Compound: Lopinavir
|
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells
|
[PMID: 12700464] |
| Caco-2 | CC50 |
2128.78 μM
Compound: LOPINAVIR
|
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
|
10.21203/rs.3.rs-23951/v1 |
| Caco-2 | IC50 |
19.11 μM
Compound: LOPINAVIR
|
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
|
10.21203/rs.3.rs-23951/v1 |
| CCRF-CEM | EC50 |
260 nM
Compound: LPV
|
Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
|
[PMID: 17576848] |
| CCRF-CEM | EC50 |
28 nM
Compound: LPV
|
Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
|
[PMID: 17576848] |
| CCRF-CEM | EC50 |
340 nM
Compound: LPV
|
Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
|
[PMID: 17576848] |
| CCRF-CEM | EC50 |
35 nM
Compound: LPV
|
Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay
|
[PMID: 17576848] |
| HEK293 | EC50 |
2.8 nM
Compound: LPV
|
Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay
Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay
|
[PMID: 17638694] |
| HEK-293T | EC50 |
160 nM
Compound: lopinavir
|
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
|
[PMID: 22148316] |
| HepG2 | CC50 |
27.8 μM
Compound: LPV
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay
|
10.1039/C1MD00147G |
| Huh-7 | CC50 |
>37.6 μM
Compound: 6a
|
Cytotoxicity against human Huh-7 cells incubated for 1 hr by MTS assay
Cytotoxicity against human Huh-7 cells incubated for 1 hr by MTS assay
|
[PMID: 32845145] |
| MDCK-II | IC50 |
10.3 μM
Compound: LPV
|
Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells
Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells
|
[PMID: 17664327] |
| MT2 | CC50 |
>100 μM
Compound: lopinavir, LPV
|
Cytotoxicity against human MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Cytotoxicity against human MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT2 | EC50 |
0.0026 μM
Compound: lopinavir, LPV
|
Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against HIV2 EHO in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT2 | EC50 |
0.0049 μM
Compound: lopinavir, LPV
|
Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against HIV2 ROD in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT2 | EC50 |
0.007 μM
Compound: lopinavir, LPV
|
Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against HIV1 LAI in MT2 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT2 | EC50 |
0.032 μM
Compound: LPV
|
Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay
Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay
|
[PMID: 18955518] |
| MT2 | EC50 |
4.8 nM
Compound: LPV
|
Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
|
[PMID: 19104010] |
| MT2 | CC50 |
>100 μM
Compound: LPV
|
Cytotoxicity against human MT2 cells after 7 days by MTT assay
Cytotoxicity against human MT2 cells after 7 days by MTT assay
|
[PMID: 20439612] |
| MT2 | EC50 |
0.028 μM
Compound: LPV
|
Antiviral activity against HIV2 ROD infected in human MT2 cells by MTT assay
Antiviral activity against HIV2 ROD infected in human MT2 cells by MTT assay
|
[PMID: 20439612] |
| MT2 | EC50 |
0.035 μM
Compound: LPV
|
Antiviral activity against HIV2 EHO infected in human MT2 cells by MTT assay
Antiviral activity against HIV2 EHO infected in human MT2 cells by MTT assay
|
[PMID: 20439612] |
| MT2 | EC50 |
0.039 μM
Compound: LPV
|
Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay
Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay
|
[PMID: 20439612] |
| MT2 | CC50 |
67.9 μM
Compound: LPV
|
Cytotoxicity against human MT2 cells assessed as reduction in cell viability after 5 days by XTT assay
Cytotoxicity against human MT2 cells assessed as reduction in cell viability after 5 days by XTT assay
|
10.1039/C1MD00147G |
| MT2 | EC50 |
5.6 nM
Compound: LPV
|
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as virus-induced cytopathic effect after 5 days by XTT assay
|
10.1039/C1MD00147G |
| MT4 | EC50 |
0.1 μM
Compound: 6 (ABT-378)
|
Effective concentration against ritonavir -resistant strains in MT-4 cells.
Effective concentration against ritonavir -resistant strains in MT-4 cells.
|
[PMID: 10669559] |
| MT4 | EC50 |
0.104 μM
Compound: ABT-378 (Lopinavir)
|
Antiviral activity against HIV in presence of 50% human serum in MT-4 cell was determined
Antiviral activity against HIV in presence of 50% human serum in MT-4 cell was determined
|
[PMID: 11378352] |
| MT4 | EC50 |
0.1 μM
Compound: 1a, ABT-378 Lopinavir
|
Compound was tested for antiviral activity against HIV-IIIB in MT-4 cells in presence of 50% human serum
Compound was tested for antiviral activity against HIV-IIIB in MT-4 cells in presence of 50% human serum
|
[PMID: 11934584] |
| MT4 | EC50 |
0.1 μM
Compound: 12a (lopinavir)
|
Antiviral activity against the cytopathic effects of HIV IIIB in MT-4 cells was assayed in the presence of 50% human serum
Antiviral activity against the cytopathic effects of HIV IIIB in MT-4 cells was assayed in the presence of 50% human serum
|
[PMID: 12372511] |
| MT4 | IC50 |
17.8 μM
Compound: 12a (lopinavir)
|
Cytotoxicity against MT-4 cells
Cytotoxicity against MT-4 cells
|
[PMID: 12372511] |
| MT4 | EC50 |
0.1 μM
Compound: 1a
|
Tested for cytopathic effect of HIVIIIB in MT-4 cells in presence of 50% human serum
Tested for cytopathic effect of HIVIIIB in MT-4 cells in presence of 50% human serum
|
[PMID: 15109669] |
| MT4 | ED50 |
0.01 μM
Compound: Lopinavir
|
Effective dose of compound required to inhibit replication of human immunodeficiency virus type 1 in MT-4 cells
Effective dose of compound required to inhibit replication of human immunodeficiency virus type 1 in MT-4 cells
|
[PMID: 15537350] |
| MT4 | IC50 |
40 nM
Compound: Lopinavir
|
Inhibitory concentration against wild type Human immuno deficiency virus (HXB2) was determined in an MT-4 cell line
Inhibitory concentration against wild type Human immuno deficiency virus (HXB2) was determined in an MT-4 cell line
|
[PMID: 15990305] |
| MT4 | IC50 |
400 nM
Compound: Lopinavir
|
Inhibitory concentration against wild type Human immuno deficiency virus (EP13) was determined in an MT-4 cell line
Inhibitory concentration against wild type Human immuno deficiency virus (EP13) was determined in an MT-4 cell line
|
[PMID: 15990305] |
| MT4 | IC50 |
>1000 nM
Compound: Lopinavir
|
Inhibitory concentration against wild type Human immuno deficiency virus (D545701) was determined in an MT-4 cell line
Inhibitory concentration against wild type Human immuno deficiency virus (D545701) was determined in an MT-4 cell line
|
[PMID: 15990305] |
| MT4 | IC50 |
40 nM
Compound: lopinavir
|
Antiviral activity against HIV1 HXB2 in MT4 cells
Antiviral activity against HIV1 HXB2 in MT4 cells
|
[PMID: 16458505] |
| MT4 | IC50 |
400 nM
Compound: lopinavir
|
Antiviral activity against HIV1 EP13 in MT4 cells
Antiviral activity against HIV1 EP13 in MT4 cells
|
[PMID: 16458505] |
| MT4 | IC50 |
>1000 nM
Compound: lopinavir
|
Antiviral activity against HIV D545701 in MT4 cells
Antiviral activity against HIV D545701 in MT4 cells
|
[PMID: 16458505] |
| MT4 | EC50 |
0.024 μM
Compound: lopinavir, LPV
|
Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against nelfinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.031 μM
Compound: lopinavir, LPV
|
Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay
Antiviral activity against HIV1 NL4-3 in MT4 cells by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.033 μM
Compound: lopinavir, LPV
|
Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against amprenavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.034 μM
Compound: lopinavir, LPV
|
Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against HIV1 GRL98065p20 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.06 μM
Compound: lopinavir, LPV
|
Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against HIV1 GRL98065p30 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.16 μM
Compound: lopinavir, LPV
|
Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against ritonavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.19 μM
Compound: lopinavir, LPV
|
Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against HIV1 GRL98065p40 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.23 μM
Compound: lopinavir, LPV
|
Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against atazanavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.26 μM
Compound: lopinavir, LPV
|
Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against idinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.27 μM
Compound: lopinavir, LPV
|
Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against saquinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
0.31 μM
Compound: lopinavir, LPV
|
Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
Antiviral activity against lopinavir-resistant HIV1 in MT4 cells assessed as inhibition of p24 Gag protein expression by MTT assay
|
[PMID: 17371811] |
| MT4 | EC50 |
15 nM
Compound: LPV
|
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 1 passage
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 1 passage
|
[PMID: 17576848] |
| MT4 | EC50 |
15 nM
Compound: LPV
|
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 17576848] |
| MT4 | EC50 |
18 nM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 17576848] |
| MT4 | EC50 |
515 nM
Compound: LPV
|
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 18 passages
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as p27 antigen level after 18 passages
|
[PMID: 17576848] |
| MT4 | EC50 |
6 nM
Compound: LPV
|
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
Antiviral activity against HIV2 MS infected in human MT4 cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
|
[PMID: 17576848] |
| MT4 | CC50 |
28 μM
Compound: LPV
|
Cytotoxicity against human MT4 cells after 6 days by MTT assay
Cytotoxicity against human MT4 cells after 6 days by MTT assay
|
[PMID: 17638694] |
| MT4 | EC50 |
0.019 μM
Compound: LPV
|
Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay
Antiviral activity against wild type HIV1 NL4-3 infected in MT4 cells after 6 days by MTT assay
|
[PMID: 17638694] |
| MT4 | EC50 |
0.01 μM
Compound: LPV, lopinavir
|
Antiviral activity against HIV1 infected MT4 cells by MTT method
Antiviral activity against HIV1 infected MT4 cells by MTT method
|
[PMID: 17696512] |
| MT4 | EC50 |
1057 nM
Compound: LPV
|
Antiviral activity against HIV1 A17 infected in human MT4 cells harboring protease L10F, V32I, M46I, I47V, Q58E, and I84V mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection meas
Antiviral activity against HIV1 A17 infected in human MT4 cells harboring protease L10F, V32I, M46I, I47V, Q58E, and I84V mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection meas
|
[PMID: 18212102] |
| MT4 | EC50 |
151 nM
Compound: LPV
|
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in presence of 50% human serum by MTT assay
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in presence of 50% human serum by MTT assay
|
[PMID: 18212102] |
| MT4 | EC50 |
18 nM
Compound: LPV
|
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
|
[PMID: 18212102] |
| MT4 | EC50 |
30 nM
Compound: LPV
|
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity after 5 days post dose by MTT assay
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity after 5 days post dose by MTT assay
|
[PMID: 18212102] |
| MT4 | EC50 |
32 nM
Compound: LPV
|
Antiviral activity against wild-type HIV1 RF infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
Antiviral activity against wild-type HIV1 RF infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay
|
[PMID: 18212102] |
| MT4 | EC50 |
3790 nM
Compound: LPV
|
Antiviral activity against HIV1 B26 infected in human MT4 cells harboring protease L33F, K45I, M46I, I50V, I54V, A71V, and V82F mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infectio
Antiviral activity against HIV1 B26 infected in human MT4 cells harboring protease L33F, K45I, M46I, I50V, I54V, A71V, and V82F mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infectio
|
[PMID: 18212102] |
| MT4 | EC50 |
>10000 nM
Compound: LPV
|
Antiviral activity against HIV1 P25 infected in human MT4 cells harboring protease L10F, G16E, V32I, M46I, I47A, H69Y, I84V, and T91S mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post in
Antiviral activity against HIV1 P25 infected in human MT4 cells harboring protease L10F, G16E, V32I, M46I, I47A, H69Y, I84V, and T91S mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post in
|
[PMID: 18212102] |
| MT4 | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA
Antiviral activity against HIV1 NL4-3 harboring L10F/L24I/M46I/L63P/A71V/G73S/V82T amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of indinavir by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
0.018 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of p24 gag protein production by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
0.025 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA
Antiviral activity against HIV1 NL4-3 harboring L23I/K43I/M46I/I50L/G51A/A71V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of atazanavir by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
0.11 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA
Antiviral activity against HIV1 NL4-3 harboring M46I/V82F/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of ritonavir by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
0.14 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by E
Antiviral activity against HIV1 NL4-3 harboring L10F/L33F/M46I/I47V/Q58E/V82I/I84V/I85V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of GRL-02031 by E
|
[PMID: 18955518] |
| MT4 | EC50 |
0.14 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA
Antiviral activity against HIV1 NL4-3 harboring L10F/V32I/M46I/I54M//A71V/I84V amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of amprenavir by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
0.29 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA
Antiviral activity against HIV1 NL4-3 harboring L10F/D30N/K45I/A71V/T74S amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of nelfinavir by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
0.3 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA
Antiviral activity against HIV1 NL4-3 harboring L10F/M46I/I54V/V82A amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 1 uM of Lopinavir by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
0.7 μM
Compound: LPV
|
Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA
Antiviral activity against HIV1 NL4-3 harboring L10I/G48V/I54V/L90M amino acid substitution in protease encoding region infected in human MT4 cells assessed as inhibition of p24 Gag protein production selected at 5 uM of saquinavir by ELISA
|
[PMID: 18955518] |
| MT4 | EC50 |
1057 nM
Compound: LPV
|
Antiviral activity against HIV1 bearing protease gene with A17 mutation infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against HIV1 bearing protease gene with A17 mutation infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19323562] |
| MT4 | EC50 |
152 nM
Compound: LPV
|
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay in presence of 50% human serum
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay in presence of 50% human serum
|
[PMID: 19323562] |
| MT4 | EC50 |
18 nM
Compound: LPV
|
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19323562] |
| MT4 | EC50 |
3790 nM
Compound: LPV
|
Antiviral activity against HIV1 bearing protease gene with B26 mutation infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against HIV1 bearing protease gene with B26 mutation infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19323562] |
| MT4 | EC50 |
>10000 nM
Compound: LPV
|
Antiviral activity against HIV1 bearing protease gene with P25 mutation infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against HIV1 bearing protease gene with P25 mutation infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19323562] |
| MT4 | EC50 |
0.016 μM
Compound: Lopinavir
|
Antiviral activity against HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 19954246] |
| MT4 | EC50 |
0.03 μM
Compound: Lopinavir
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 19954246] |
| MT4 | EC50 |
0.385 μM
Compound: Lopinavir
|
Antiviral activity against indinavir-resistant HIV1 harboring L10R/M46I/L63P/V82T/I84V mutant protease infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against indinavir-resistant HIV1 harboring L10R/M46I/L63P/V82T/I84V mutant protease infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 19954246] |
| MT4 | EC50 |
10 nM
Compound: LPV
|
Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 6 days by XTT assay
Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 6 days by XTT assay
|
[PMID: 19961222] |
| MT4 | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay
Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay
Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay
Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells selected at 5 uM of atazanavir by MTT assay
Antiviral activity against HIV1 expressing protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells selected at 5 uM of atazanavir by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
0.037 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay
Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
0.046 μM
Compound: LPV
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
0.12 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay
Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
0.19 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay
Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
0.28 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay
Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay
|
[PMID: 20439612] |
| MT4 | EC50 |
0.33 μM
Compound: LPV
|
Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay
Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay
|
[PMID: 20439612] |
| MT4 | IC50 |
0.035 μM
Compound: Lopinavir
|
Cytotoxicity against human MT4 cells after 5 days by XTT assay
Cytotoxicity against human MT4 cells after 5 days by XTT assay
|
[PMID: 21741133] |
| MT4 | EC50 |
152 nM
Compound: LPV
|
Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay in presence of 50% human serum
Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay in presence of 50% human serum
|
[PMID: 21899332] |
| MT4 | EC50 |
18 nM
Compound: LPV
|
Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay
Antiviral activity against wild type HIV1 pNL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cell death after 5 days by MTT assay
|
[PMID: 21899332] |
| MT4 | CC50 |
>10 μM
Compound: Lopinavir
|
Cytotoxicity against human MT4 cells
Cytotoxicity against human MT4 cells
|
[PMID: 23177258] |
| MT4 | EC50 |
110 nM
Compound: Lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/M46I/I64V/I84V/L90M/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/M46I/I64V/I84V/L90M/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication
|
[PMID: 23177258] |
| MT4 | EC50 |
13 nM
Compound: Lopinavir
|
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication
|
[PMID: 23177258] |
| MT4 | EC50 |
310 nM
Compound: Lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/I13V/M46I/I50V/L63P/L76V protease mutant infected in human MT4 cells assessed as inhibition of viral replication
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/I13V/M46I/I50V/L63P/L76V protease mutant infected in human MT4 cells assessed as inhibition of viral replication
|
[PMID: 23177258] |
| MT4 | EC50 |
32 nM
Compound: Lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/K20R/M36I/G48V/ I62V/A71V/V82A/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication
Antiviral activity against Human immunodeficiency virus 1 3B clinical isolate harboring L10I/K20R/M36I/G48V/ I62V/A71V/V82A/I93L protease mutant infected in human MT4 cells assessed as inhibition of viral replication
|
[PMID: 23177258] |
| MT4 | EC50 |
63 nM
Compound: Lopinavir
|
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication in presence of 50% human plasma
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication in presence of 50% human plasma
|
[PMID: 23177258] |
| MT4 | CC50 |
9.8 μM
Compound: lopinavir
|
Cytotoxicity against human MT4 cells
Cytotoxicity against human MT4 cells
|
[PMID: 24900331] |
| MT4 | EC50 |
114.6 nM
Compound: lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 isolate M1 expressing protease L10I, M46I, I64V, I84V, L90M, I93L mutant infected in human MT4 cells
Antiviral activity against Human immunodeficiency virus 1 isolate M1 expressing protease L10I, M46I, I64V, I84V, L90M, I93L mutant infected in human MT4 cells
|
[PMID: 24900331] |
| MT4 | EC50 |
13.2 nM
Compound: lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells
|
[PMID: 24900331] |
| MT4 | EC50 |
307.3 nM
Compound: lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 isolate M2 expressing protease L10I, I13V, M46I, I50V, L63P, L76V mutant infected in human MT4 cells
Antiviral activity against Human immunodeficiency virus 1 isolate M2 expressing protease L10I, I13V, M46I, I50V, L63P, L76V mutant infected in human MT4 cells
|
[PMID: 24900331] |
| MT4 | EC50 |
32.1 nM
Compound: lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 isolate M3 expressing protease L10I, K20R, M36I, G48V, I62V, A71V, V82A, I93L mutant infected in human MT4 cells
Antiviral activity against Human immunodeficiency virus 1 isolate M3 expressing protease L10I, K20R, M36I, G48V, I62V, A71V, V82A, I93L mutant infected in human MT4 cells
|
[PMID: 24900331] |
| MT4 | EC50 |
63.2 nM
Compound: lopinavir
|
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells in presence of 50% human serum
Antiviral activity against Human immunodeficiency virus 1 3B expressing wild-type protease infected in human MT4 cells in presence of 50% human serum
|
[PMID: 24900331] |
| PBMC | EC50 |
15 nM
Compound: LPV
|
Antiviral activity against HIV2 MS infected in human PBMC cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
Antiviral activity against HIV2 MS infected in human PBMC cells assessed as inhibition of virus production after 5 days by Lenti-RT activity assay
|
[PMID: 17576848] |
| PBMC | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against multidrug-resistant HIV1 isolate B containing protease L10I, K14R, L33I, M36I,M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
Antiviral activity against multidrug-resistant HIV1 isolate B containing protease L10I, K14R, L33I, M36I,M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
|
[PMID: 20439612] |
| PBMC | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against multidrug-resistant HIV1 isolate C containing protease L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q, V82A, and L89M mutant infected in human PHA-PBMC cells by MTT assay
Antiviral activity against multidrug-resistant HIV1 isolate C containing protease L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q, V82A, and L89M mutant infected in human PHA-PBMC cells by MTT assay
|
[PMID: 20439612] |
| PBMC | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against multidrug-resistant HIV1 isolate JSL containing L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, and V82A mutant infected in human PHA-PBMC cells by MTT assay
Antiviral activity against multidrug-resistant HIV1 isolate JSL containing L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, and V82A mutant infected in human PHA-PBMC cells by MTT assay
|
[PMID: 20439612] |
| PBMC | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against multidrug-resistant HIV1 isolate MM containing L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, and Q92K mutant infected in human PHA-PBMC cells by MTT assay
Antiviral activity against multidrug-resistant HIV1 isolate MM containing L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, and Q92K mutant infected in human PHA-PBMC cells by MTT assay
|
[PMID: 20439612] |
| PBMC | EC50 |
>1 μM
Compound: LPV
|
Antiviral activity against multidrug-resistant HIV1 isolate TM containing L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
Antiviral activity against multidrug-resistant HIV1 isolate TM containing L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, and I93L mutant infected in human PHA-PBMC cells by MTT assay
|
[PMID: 20439612] |
| PBMC | EC50 |
0.034 μM
Compound: LPV
|
Antiviral activity against wild type HIV1 ERS104 containing protease L36P mutant infected in human PHA-PBMC cells by MTT assay
Antiviral activity against wild type HIV1 ERS104 containing protease L36P mutant infected in human PHA-PBMC cells by MTT assay
|
[PMID: 20439612] |
| PBMC | EC50 |
0.26 μM
Compound: LPV
|
Antiviral activity against multidrug-resistant HIV1 isolate G containing L10I, V11I, T12E, I15V, L19I,R41K, M46L, L63P, A71T, V82A, and L90M mutant infected in human PHA-PBMC cells by MTT assay
Antiviral activity against multidrug-resistant HIV1 isolate G containing L10I, V11I, T12E, I15V, L19I,R41K, M46L, L63P, A71T, V82A, and L90M mutant infected in human PHA-PBMC cells by MTT assay
|
[PMID: 20439612] |
| PBMC | EC50 |
>0.16 μM
Compound: 6; LPV
|
Antiviral activity against multidrug-resistant HIV1-G infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against multidrug-resistant HIV1-G infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
>0.3 μM
Compound: 6; LPV
|
Antiviral activity against multidrug-resistant HIV1-B infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against multidrug-resistant HIV1-B infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
>0.36 μM
Compound: 6; LPV
|
Antiviral activity against multidrug-resistant HIV1-TM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against multidrug-resistant HIV1-TM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
>0.38 μM
Compound: 6; LPV
|
Antiviral activity against multidrug-resistant HIV1-MM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against multidrug-resistant HIV1-MM infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
>0.4365 μM
Compound: 6; LPV
|
Antiviral activity against multidrug-resistant HIV1-C infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against multidrug-resistant HIV1-C infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
>0.7 μM
Compound: 6; LPV
|
Antiviral activity against multidrug-resistant HIV1-JSL infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against multidrug-resistant HIV1-JSL infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
>1000 nM
Compound: 6; LPV
|
Antiviral activity against darunavir-resistant HIV1 20P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against darunavir-resistant HIV1 20P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
0.007 μM
Compound: 6; LPV
|
Antiviral activity against wild type HIV1 ERS104pre infected in human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against wild type HIV1 ERS104pre infected in human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| PBMC | EC50 |
>1000 nM
Compound: 6; LPV
|
Antiviral activity against darunavir-resistant HIV1 10P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
Antiviral activity against darunavir-resistant HIV1 10P infected in phytohemagglutinin-activated human PBMC cells assessed as inhibition of virus-induced cytopathic effect measured after 7 days by MTT assay
|
[PMID: 26799988] |
| Vero | CC50 |
>50 μM
Compound: Lopinavir
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
9.12 μM
Compound: Lopinavir
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
| Vero C1008 | CC50 |
>32 μM
Compound: 6a
|
Cytotoxicity against African green monkey Vero E6 cells incubated for 3 days by the MTS assay
Cytotoxicity against African green monkey Vero E6 cells incubated for 3 days by the MTS assay
|
[PMID: 32845145] |
| Vero C1008 | EC50 |
26.1 μM
Compound: 11
|
Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay
Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay
|
[PMID: 33486200] |
HIV-1 protease is an essential enzyme for production of mature, infective virus[1].
Lopinavir potently inhibits wild-type and mutant HIV protease (Ki= 1.3 to 3.6 pM), blocks the replication HIV type 1 (EC50=0.006 to 0.017 μM), and maintains high potency against mutant HIV selected by Ritonavir in vivo (EC50=≤0.06 μM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 192725-17-0
-
Appearance Solid
-
Molecular Weight 628.80
-
Formula C37H48N4O5
-
Color White to off-white
-
SMILES
CC1=C(OCC(N[C@@H](CC2=CC=CC=C2)[C@@H](O)C[C@H](CC3=CC=CC=C3)NC([C@H](C(C)C)N4C(NCCC4)=O)=O)=O)C(C)=CC=C1
-
Synonyms
ABT-378
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. [Abstract]2021 May 29;6(1):212. PMID: 34052830 -
Cancer Cell
2024 Nov 11;42(11):1955-1969.e7. PMID: 39532065 -
Nat Commun
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. [Abstract]2020 Sep 4;11(1):4417. PMID: 32887884 -
Bone Res
AIDS patients suffer higher risk of advanced knee osteoarthritis progression due to lopinavir-induced Zmpste24 inhibition. [Abstract]2025 Jun 3;13(1):58. PMID: 40461512
Lopinavir purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Jun 3;13(1):58. [Abstract]
Lopinavir (100 or 200 mg/kg)/ritonavir (25 or 50 mg/kg) i.p., every 2 days for 28 days) aggravated osteophyte formation in the DMM model.
Lopinavir purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Jun 3;13(1):58. [Abstract]
Lopinavir (100 or 200 mg/kg)/ritonavir (25 or 50 mg/kg, i.p., every 2 days for 28 days) aggravated cartilage erosion and synovitis in the DMM model.
Lopinavir purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Jun 3;13(1):58. [Abstract]
Lopinavir (100 or 200 mg/kg)/ritonavir (25 or 50 mg/kg, i.p., every 2 days for 28 days) decreased the proportion of Sox9-positive cells from 36% to 18% and increased the proportion of p21-positive cells from 32% to 60%.
-
Adv Sci (Weinh)
The Compromised Fanconi Anemia Pathway in Prelamin A-Expressing Cells Contributes to Replication Stress-Induced Genomic Instability. [Abstract]2024 Jun 18:e2307751. PMID: 38894550 -
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Fundam Res
2023 Apr 7;5(6):2975-2982. PMID: 41467005 -
-
Int J Antimicrob Agents
2019 Dec;54(6):814-819. PMID: 31479744 -
Antimicrob Agents Chemother
2020 Aug 20;64(9):e00872-20. PMID: 32669265 -
Antiviral Res
HIV protease inhibitor attenuated astrocyte autophagy involvement in inflammation via p38 MAPK pathway. [Abstract]2022 Dec:208:105463. PMID: 36372295
Lopinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Dec:208:105463. [Abstract]
Lopinavir (LPV) (1, 5, 10, 20, 50 µM; 12, 24, 36, 48 h) inhibits the growth of U87 cells.
Lopinavir purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2022 Dec:208:105463. [Abstract]
Lopinavir (LPV) (0, 1, 5, 10, 20 μM; 24 h) inhibits autophagy in U87 cells in a dose-dependent manner.
-
Antiviral Res
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. [Abstract]2020 Jun;178:104786. PMID: 32251767 -
Viruses
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]2020 Jun 10;12(6):628. PMID: 32532085 -
-
Biochem Biophys Res Commun
HIV protease inhibitors block parasite signal peptide peptidases and prevent growth of Babesia microti parasites in erythrocytes. [Abstract]2019 Sep 10;517(1):125-131. PMID: 31311649 -
-
-
-
Solvent & Solubility
DMSO : 250 mg/mL (397.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.31 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Corn Oil
Solubility: 20 mg/mL (31.81 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cvetkovic RS, et al. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63(8):769-802. [Content Brief]
[2]. Sham HL, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42(12):3218-3224. [Content Brief]
[3]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5903 mL | 7.9517 mL | 15.9033 mL | 39.7583 mL |
| 5 mM | 0.3181 mL | 1.5903 mL | 3.1807 mL | 7.9517 mL | |
| 10 mM | 0.1590 mL | 0.7952 mL | 1.5903 mL | 3.9758 mL | |
| 15 mM | 0.1060 mL | 0.5301 mL | 1.0602 mL | 2.6506 mL | |
| 20 mM | 0.0795 mL | 0.3976 mL | 0.7952 mL | 1.9879 mL | |
| 25 mM | 0.0636 mL | 0.3181 mL | 0.6361 mL | 1.5903 mL | |
| 30 mM | 0.0530 mL | 0.2651 mL | 0.5301 mL | 1.3253 mL | |
| 40 mM | 0.0398 mL | 0.1988 mL | 0.3976 mL | 0.9940 mL | |
| 50 mM | 0.0318 mL | 0.1590 mL | 0.3181 mL | 0.7952 mL | |
| 60 mM | 0.0265 mL | 0.1325 mL | 0.2651 mL | 0.6626 mL | |
| 80 mM | 0.0199 mL | 0.0994 mL | 0.1988 mL | 0.4970 mL | |
| 100 mM | 0.0159 mL | 0.0795 mL | 0.1590 mL | 0.3976 mL |